What’s happening, and where you can meet us and our suppliers in person.

Element Biosciences Launches New Product

SAN DIEGO, CA (October 16, 2024) – Element Biosciences, Inc., a developer of pioneering technologies to empower science, today introduced Trinity™ - an innovative solution that simplifies target capture sequencing by eliminating or moving traditionally time-consuming steps to the AVITI™ System and providing customers with the option to dramatically reduce hybridization time, without sacrificing cost or quality.

More information can be found on the press release

Find out more >>

Element Biosciences Inc

AVITITM System now available for our customers in Iraq, Jordan, Lebanon and Libya

We are happy to share some exciting news with you. Our company has recently signed a distributor agreement with Element Biosciences to make its AVITI™ System available to more customers in Iraq, Jordan, Lebanon and Libya.
The AVITI™System is an advanced DNA sequencing platform that is changing the way genomics research is done. It is in high demand around the world, and this partnership with Element Biosciences allows us to bring it to our customers.
Labs around the world have shown great interest in the AVITI™ System because it offers high-quality, affordable, and easy-to-use genomics tools that accelerate discovery.
We are enthusiastic about making the AVITI™ System more accessible, and we hope that this news is as exciting for you as it is for us. If you have any questions or need more information, please feel free to reach out.



About Element Biosciences, Inc.

Element Biosciences is a pioneering life science company developing innovative technologies that empower the scientific community with more freedom and flexibility to accelerate their scientific discoveries. By reinventing every fundamental element of the assay system, we’ve created disruptive DNA sequencing and multiomics tools, including our family of AVITI™ systems. The AVITI benchtop instrument uses proprietary technology to deliver high-quality sequencing at low run costs, accessible for any scale of research operation.  Leveraging our revolutionary technology, we are adding to these capabilities, improving standard workflows, and providing multiomic readouts. Together, these innovations drive impactful discoveries that benefit humanity.

Find out more >>

Collaboration with Poietis

We are happy to announce our collaboration with Poietis, a company with headquarters in Bordeaux, France. Together with Poietis our mission is to provide solutions leveraging a proprietary, innovative Next-Generation Bioprinting platform and bring Tissue Engineering therapies to patients.
Poietis is a spin-off from INSERM and University of Bordeaux where Laser-Assisted Bioprinting Technology was initially developed. On the basis of its expertise in high resolution Laser-Assisted Bioprinting (LAB), Poietis has developed the Next-Generation Bioprinting (NGB) platform.

 

 

Find out more >>

25 YEARS HVD LIFE SCIENCES

Celebrate with us

More than 25 years in delivering a specialised, streamlined sales process, expert customer support and top quality service! Our core values include continuity and loyalty towards the people we work with: not only customers and suppliers but also to our employees and business partners.
Together we have been Delivering Life Sciences to the World for more than 25 years.

Find out more >>

New in our portfolio

Collaboration with CalibreScientific

We are happy to announce our collaboration with Calibre Scientific, a company with headquarters in Los Angeles, California, representing a diverse portfolio of niche life sciences companies in the fields cell & molecular biology, proteomics, applied science & diagnostics.

Find out more >>

HVD Vertrieb awarded by Ministry of Health

MOHAP Award

In September 2018, the United Arab Emirates, Ministry Of Health and Preventive has awarded HVD Vertriebs Ges.m.b.H a dedicated certificate for best services provided to them in 2017.

Find out more >>

Product News ViennaLab 2018

ViennaLab releasing the first series of multiplex (mpx) RealFast™ Assays

The ViennaLab multiplex RealFast™ Assays allow to genotype two loci simultaneously and thus save costs and sample material.

 

Find out more >>

Product News Attana 2018

Attana expands collaboration with HVD Life Sciences

Find out more >>

Product News Gyros 2018

Gyros Protein Technologies introduces Gyrolab xPand to improve immunoassay workflow, flexibility and speed in biotherapeutic discovery, development and production

Find out more >>

Product News Gyros 05/2017

Gyros Protein Technologies introduces next generation Gyrolab Protein A Kit for Biotherapeutics

Kit increases efficiency of residual protein A ligand detection

Uppsala, Sweden, May 10 , 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced it has launched a new version of its Gyrolab™ Protein A Kit.

Find out more >>

Product News Gyros 04/2017

Gyros Protein Technologies introduces a multi-species kit for pharmacokinetic studies

New kit for early-stage biotherapeutic development, optimized for use in Gyrolab™ systems

Uppsala, Sweden, 05 April 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced today it has introduced a new kit for early-stage biotherapeutic pharmacokinetic (PK) studies.

Find out more >>

PRODUCT NEWS Gyros 04/2016

Gyros: Finding the best platform for fit-for-purpose ADA assays

Gyrolab system delivers

 

Determining the immunogenic potential of a therapeutic antibody is a regulatory requirement during clinical development since anti-drug antibodies (ADA) can cause undesirable effects, ranging from loss of drug exposure and efficacy to serious adverse events. Justine Brose and her colleagues at Novimmune SA, Geneva, Switzerland evaluated four platforms to determine which platform and sample pre-treatment procedures could deliver a fit-for-purpose assay for ADA analysis to determine the immunogenicity of the therapeutic antibody Novimab. Of the platforms tested (ELISA and Gyrolab, Meso Scale Discovery, and AlphaLISA platforms) only Gyrolab and MSD platforms met all of their pre-specified assay requirements.

 

Read more >>

Find out more >>

PRODUCT NEWS ViennaLab 05/2015

ViennaLab introduces the RealFast™ Assay!

Find out more >>

PRODUCT NEWS Gyros 05/2015

Gyros has developed a sandwich immunoassay kit specific for Chinese Hamster Ovary (CHO) HCP impurities...

Find out more >>

PRODUCT NEWS 02/2015


Gyros Launches Nanoliter-scale Immunoassay System Gyrolab xPlore™ at SLAS2015 Conference

Find out more >>

PRODUCT NEWS 01/2015


Abacus Diagnostica is first on the market with a CE IVD marked ultra-sensitive POCT GBS!

Find out more >>